Ilosone

Gastroparesis, Erythrasma, Whooping Cough + 60 more
Treatment
68 FDA approvals
20 Active Studies for Ilosone

What is Ilosone

ErythromycinThe Generic name of this drug
Treatment SummaryErythromycin is an antibiotic drug used to treat various bacterial infections. It was first discovered in 1952 and belongs to a group of antibiotics called macrolides, which includes Azithromycin, Clarithromycin, and Spiramycin. It can be administered in different forms, such as intravenously, topically, or as eye drops.
Erythrocin Stearateis the brand name
Ilosone Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Erythrocin Stearate
Erythromycin
1964
261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Corynebacterium minutissimum infection and Recurrent Upper and Lower Respiratory Tract Infections (RTIs) .
Corynebacterium minutissimum infection
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
penicillins
prophylaxis of Postoperative Infections
Erythrasma
Streptococcus Pneumoniae Infections
Communicable Diseases
Diphtheria
Corynebacterium Infections
diphtheria antitoxin
Upper Respiratory Tract Infection
Streptococcus pyogenes
Corynebacterium Infections
prophylaxis of Rheumatic fever
Urinary Tract Infection (UTI)
Pertussis
uncomplicated endocervical infection
Skin and skin structure infections
Staphylococcus (S.) Aureus Infection
Urethritis
Urethritis
Primary Syphilis
Lower Respiratory Tract Infection (LRTI)
Communicable Diseases
pustular lesions
Used to treat pustular lesions in combination with Avobenzone
urogenital infections during pregnancy
Haemophilus Influenzae Infections
Used to treat Haemophilus Influenzae Infections in combination with null
Urethritis
Ureaplasma urealyticum
skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes
Acne Vulgaris
Used to treat Acne Vulgaris in combination with Tretinoin
Acne Vulgaris
Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin
penicillins
Ureaplasma urethritis
Legionella pneumophila
Intestinal amebiasis caused by entamoeba histolytica
Conjunctivitis
Listeria infection
treponema pallidum infection
Bacterial Infections
Communicable Diseases
Respiratory Tract Infections
Listeriosis
Communicable Diseases
Bacterial Infections
Whooping Cough
Amebiasis
Common Cold
Rheumatic Fever
Staphylococcal Skin Infections
Bronchitis
Pneumonia, Mycoplasma
Postoperative Infections
Staphylococcal Skin Infections
Whooping Cough
Bordetella Pertussis Infection
Pneumonia
Listeria monocytogenes infection
Acute Otitis Media caused by Haemophilus Influenzae
Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole
inflammatory papular lesions
Used to treat inflammatory papular lesions in combination with Avobenzone
Whooping Cough
Chlamydia Trachomatis
patients with intolerance or contraindications to tetracycline use
Syphilis
First episode of rheumatic fever
Rheumatic Fever
Pneumococcal Infections
Sulfonamides

Effectiveness

How Ilosone Affects PatientsErythromycin is an antibiotic that works by stopping bacteria from producing proteins. It is effective in treating some bacterial infections, but it is important to check for bacterial resistance before prescribing it. Combining erythromycin with sulfonamides is often more effective at treating Haemophilus influenzae infections than just erythromycin alone. However, Staphylococci may develop resistance to erythromycin. Pseudomembranous colitis, a serious intestinal problem, is a possible side effect of taking erythromycin. Erythromycin can also cause liver
How Ilosone works in the bodyErythromycin works to prevent bacteria from replicating. It does this by blocking a specific step in the process of protein synthesis. This step involves building the ribosomal proteins that are necessary for the bacteria to reproduce. By blocking this step, erythromycin stops bacteria from producing the proteins they need and prevents them from multiplying. This is why erythromycin is effective against a wide range of bacterial infections.

When to interrupt dosage

The proposed dose of Ilosone is contingent upon the diagnosed affliction, comprising Chlamydia Trachomatis, penicillins and Syphilis. The amount of dosage shifts as per the method of delivery (e.g. Granule, for suspension or Tablet, film coated - Oral) outlined in the table hereunder.
Condition
Dosage
Administration
Conjunctivitis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Rheumatic Fever
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Corynebacterium Infections
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
pustular lesions
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
inflammatory papular lesions
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Acute Otitis Media caused by Haemophilus Influenzae
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Gastroparesis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Erythrasma
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Whooping Cough
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Chancroid
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Diphtheria
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Lymphogranuloma Venereum
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Granuloma Inguinale
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Urethritis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Whooping Cough
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Acne Vulgaris
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Listeriosis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Endophthalmitis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Bacterial Infections
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Ophthalmia neonatorum (gonococcal)
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

Ilosone has nine contraindications and should not be used when encountering any of the conditions presented in the following table.Ilosone Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Erythromycin may interact with Pulse Frequency
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Ilosone.
Common Ilosone Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Erythromycin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Erythromycin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Erythromycin.
Ilosone Toxicity & Overdose RiskThe lowest toxic dose of erythromycin for rats is 9272mg/kg. Overdosing on erythromycin can cause diarrhea, nausea, stomach cramps, and vomiting. If an overdose occurs, erythromycin should be stopped and any unabsorbed drug should be removed as quickly as possible. Supportive measures should also be taken. Unfortunately, this drug cannot be removed from the bloodstream through dialysis.
image of a doctor in a lab doing drug, clinical research

Ilosone Novel Uses: Which Conditions Have a Clinical Trial Featuring Ilosone?

53 active trials are currently underway to determine the effectiveness of Ilosone in managing Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.
Condition
Clinical Trials
Trial Phases
Acne Vulgaris
0 Actively Recruiting
Primary Syphilis
0 Actively Recruiting
urogenital infections during pregnancy
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Urethritis
0 Actively Recruiting
Chlamydia Trachomatis
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Common Cold
3 Actively Recruiting
Not Applicable
Legionella pneumophila
0 Actively Recruiting
Listeriosis
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
treponema pallidum infection
0 Actively Recruiting
Corynebacterium minutissimum infection
0 Actively Recruiting
Listeria monocytogenes infection
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Ureaplasma urealyticum
0 Actively Recruiting
Acute Otitis Media caused by Haemophilus Influenzae
0 Actively Recruiting
Pneumococcal Infections
0 Actively Recruiting
patients with intolerance or contraindications to tetracycline use
0 Actively Recruiting
Whooping Cough
0 Actively Recruiting

Ilosone Reviews: What are patients saying about Ilosone?

1.3Patient Review
8/5/2008
Ilosone for Strep Throat
I was treated for strep throat with this medication for almost a month when I was in college. One day, I started feeling disoriented and then fainted during class. It turns out that the drug had caused me to become jaundiced, and I had to be hospitalized as a result.

Patient Q&A Section about ilosone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What bacteria is erythromycin used to treat?

"Erythromycin is used to treat infections caused by bacteria including Streptococcus, Staphylococcus, Haemophilus, and Corynebacterium genera. These bacteria typically infect the skin and upper respiratory tract."

Answered by AI

What is the generic name of ilosone?

"Erythromycin is the generic name of a medication that is used to treat bacterial infections. The medication is medically reviewed by Drugs.com, and the most recent review was conducted on March 7, 2022."

Answered by AI

What is ilosone used for?

"Erythromycin can be used to treat infections in different parts of the body, including the respiratory tract, skin, and intestines. It can also be used to prevent and treat diseases such as Legionnaire's disease, pertussis, and syphilis."

Answered by AI

What is Erythrocin for?

"The active ingredient in Erythrocin Tablets is erythromycin, which is a type of macrolide antibiotic. These tablets are used to prevent and treat infections such as throat and sinus infections, as well as chest infections such as bronchitis and pneumonia."

Answered by AI

Clinical Trials for Ilosone

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
Recruiting
Has No Placebo
Children's Healthcare of Atlanta (+3 Sites)Todd Florin, MD, MSCE
Have you considered Ilosone clinical trials? We made a collection of clinical trials featuring Ilosone, we think they might fit your search criteria.Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA
Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.
Waitlist Available
Has No Placebo
Children's Community Pediatrics Brentwood (+1 Sites)Timothy R Shope, MD, MPHMerck Sharp & Dohme LLC
Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada
The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).
Recruiting
Has No Placebo
Maternity Centre of HamiltonLaura K Erdman, MD PhD FRCPC
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Have you considered Ilosone clinical trials? We made a collection of clinical trials featuring Ilosone, we think they might fit your search criteria.Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA
The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.
Waitlist Available
Has No Placebo
University of Pennsylvania Primary Care Practice
Have you considered Ilosone clinical trials? We made a collection of clinical trials featuring Ilosone, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security